To determine whether chemerin treatment influences EMT in breast cancer cells, we investigated the expression level of E-cadherin as an epithelial marker and those of vimentin and β-catenin as mesenchymal markers in MDA-MB-231 and MCF-7 cells exposed to chemerin. Here, RARRES2 is linked to breast carcinoma.